search
Back to results

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia (TRONCHER)

Primary Purpose

COVID19, Intensive Care Unit

Status
Unknown status
Phase
Phase 3
Locations
Tunisia
Study Type
Interventional
Intervention
Tocilizumab Injection
Deferoxamine
Sponsored by
Abderrahmane Mami Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COVID19 focused on measuring Deferoxamine, Tocilizumab

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient confirmed COVID19 positive
  • Patient with acute respiratory deficiency
  • Patient hospitalized in the intensive care unit
  • Age >18 years old
  • Having given written consent for their participation in the study

Exclusion Criteria:

  • Taking Tocilizumab or hydroxychloroquine deferoxamine within one month prior to inclusion (excluding participation in THINC or COVID_2Pro or COVID+PA studies)
  • Severe/severe liver failure
  • Dialysis patients
  • Renal insufficiency (clearance< 30ml/min/1.73m2)
  • Allergy to deferoxamine
  • Pregnant or breastfeeding woman
  • Hypersensitivity to the active substance or any of the excipients of Tocilizumab
  • A decrease in blood platelets with previous use of enoxaparin or another heparin drug,
  • hemophilia and related diseases,
  • stomach or duodenal ulcer

Sites / Locations

  • Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Tocilizumab

Deferoxamine

Arm Description

ROACTEMRA: (8mg/ kg per day) (1 injection per infusion)

DESFERAL: 500 mg, powder, and solvent for IV solution

Outcomes

Primary Outcome Measures

the mortality rate
Evaluate the mortality rate at 90 days. Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)

Secondary Outcome Measures

Full Information

First Posted
April 22, 2020
Last Updated
August 26, 2020
Sponsor
Abderrahmane Mami Hospital
Collaborators
Eshmoun Clinical Research Center, Datametrix
search

1. Study Identification

Unique Protocol Identification Number
NCT04361032
Brief Title
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia
Acronym
TRONCHER
Official Title
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Unknown status
Study Start Date
September 4, 2020 (Anticipated)
Primary Completion Date
September 4, 2020 (Anticipated)
Study Completion Date
October 4, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Abderrahmane Mami Hospital
Collaborators
Eshmoun Clinical Research Center, Datametrix

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.
Detailed Description
Arm1 : Usual standard treatment* Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion) a second injection may be considered if necessary, but no more than 800 mg per day. Only on the 1st day (D0) Enoxaparin (4000 IU X 2) per day for the duration of hospitalization VERSUS Arm 2: Usual standard treatment* Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution) by electric syringe 40 mg/kg/day 5day/7 without exceeding 5 g per day for 14 days Enoxaparin (4000 IU X 2) per day for the duration of hospitalization Usual standard treatment*: according to the standard practices of each center, apart from the active molecules of the 2 arms and their therapeutic class)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID19, Intensive Care Unit
Keywords
Deferoxamine, Tocilizumab

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
260 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tocilizumab
Arm Type
Experimental
Arm Description
ROACTEMRA: (8mg/ kg per day) (1 injection per infusion)
Arm Title
Deferoxamine
Arm Type
Active Comparator
Arm Description
DESFERAL: 500 mg, powder, and solvent for IV solution
Intervention Type
Drug
Intervention Name(s)
Tocilizumab Injection
Other Intervention Name(s)
ROACTEMRA
Intervention Description
Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)
Intervention Type
Drug
Intervention Name(s)
Deferoxamine
Other Intervention Name(s)
DESFERAL
Intervention Description
Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)
Primary Outcome Measure Information:
Title
the mortality rate
Description
Evaluate the mortality rate at 90 days. Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)
Time Frame
90 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient confirmed COVID19 positive Patient with acute respiratory deficiency Patient hospitalized in the intensive care unit Age >18 years old Having given written consent for their participation in the study Exclusion Criteria: Taking Tocilizumab or hydroxychloroquine deferoxamine within one month prior to inclusion (excluding participation in THINC or COVID_2Pro or COVID+PA studies) Severe/severe liver failure Dialysis patients Renal insufficiency (clearance< 30ml/min/1.73m2) Allergy to deferoxamine Pregnant or breastfeeding woman Hypersensitivity to the active substance or any of the excipients of Tocilizumab A decrease in blood platelets with previous use of enoxaparin or another heparin drug, hemophilia and related diseases, stomach or duodenal ulcer
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eshmoun Clinical Research Centre
Phone
0021627870563
Email
eshmouncompany@eshmoun.com.tn
First Name & Middle Initial & Last Name or Official Title & Degree
Chokri Jeribi, Dr
Phone
+21627870563
Facility Information:
Facility Name
Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana
City
Ariana
Country
Tunisia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chokri Jeribi, Dr
Phone
+21627870563
Email
eshmouncompany@eshmoun.com.tn

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

We'll reach out to this number within 24 hrs